Roger E. McLendon
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.02%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
Papers in
- Genetics 157
- Glioma Diagnosis and Treatment 157
-
- Chromatin Remodeling and Cancer 18
- Co-authors
- Darell D. Bigner (127 shared papers)Jeremy N. Rich (55 shared papers)Anita B. Hjelmeland (16 shared papers)Henry S. Friedman (102 shared papers)Allan H. Friedman (72 shared papers)Shideng Bao (9 shared papers)Qiulian Wu (10 shared papers)Qing Shi (4 shared papers)
- Journals
- Neuro-Oncology (26 papers)Journal of Neuro-Oncology (20 papers)Journal of Clinical Oncology (19 papers)Cancer (16 papers)Archives of Pathology & Laboratory Medicine (13 papers)
- Partner nations
- United StatesCanadaChina
In The Last Decade
Roger E. McLendon
325 papers receiving 41.7k citations
Roger E. McLendon's Hit Papers
Peers
Comparison fields: 5 of 168
- Genetics 17.1k
- Cancer Research 10.2k
- Oncology 11.3k
- Molecular Biology 17.4k
- Immunology 4.7k
Countries citing papers authored by Roger E. McLendon
This map shows the geographic impact of Roger E. McLendon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger E. McLendon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger E. McLendon more than expected).
Fields of papers citing papers by Roger E. McLendon
This network shows the impact of papers produced by Roger E. McLendon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger E. McLendon. The network helps show where Roger E. McLendon may publish in the future.
Co-authors
The 25 scholars most cited alongside Roger E. McLendon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 331 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Comprehensive genomic characterization defines human glioblastoma genes and core pathways Hit paper breakdown → | 2008 | 5756 |
| 2 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Hit paper breakdown → | 2006 | 4880 |
| 3 | IDH1andIDH2Mutations in Gliomas Hit paper breakdown → | 2009 | 4289 |
| 4 | Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells Hit paper breakdown → | 2009 | 1054 |
| 5 | Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor Hit paper breakdown → | 2006 | 1027 |
| 6 | Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth Hit paper breakdown → | 2015 | 708 |
| 7 | Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth Hit paper breakdown → | 2013 | 671 |
| 8 | The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype Hit paper breakdown → | 2009 | 624 |
| 9 | Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma Hit paper breakdown → | 2010 | 615 |
| 10 | Recurrent Glioblastoma Treated with Recombinant Poliovirus Hit paper breakdown → | 2018 | 597 |
| 11 | Phase II Trial of Gefitinib in Recurrent Glioblastoma Hit paper breakdown → | 2003 | 560 |
| 12 | 2010 | 488 | |
| 13 | A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo Hit paper breakdown → | 2016 | 481 |
| 14 | 2015 | 414 | |
| 15 | Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. | 1995 | 383 |
| 16 | 2011 | 371 | |
| 17 | A public database for gene expression in human cancers. | 1999 | 344 |
| 18 | 2008 | 333 | |
| 19 | 2008 | 329 | |
| 20 | 2010 | 326 |
About Roger E. McLendon
Roger E. McLendon is a scholar working on Genetics, Molecular Biology, Oncology, Neurology and Radiology, Nuclear Medicine and Imaging, having authored 331 papers that have together received 42.4k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (157 papers), Neuroblastoma Research and Treatments (31 papers), Brain Metastases and Treatment (26 papers), Radiopharmaceutical Chemistry and Applications (22 papers), Cancer Cells and Metastasis (21 papers), Meningioma and schwannoma management (20 papers), Chromatin Remodeling and Cancer (18 papers) and Immunotherapy and Immune Responses (17 papers). The work is most often cited by research in Genetics (17.1k citations), Cancer Research (10.2k citations), Oncology (11.3k citations), Molecular Biology (17.4k citations) and Immunology (4.7k citations). Roger E. McLendon has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Darell D. Bigner, Jeremy N. Rich, Anita B. Hjelmeland, Henry S. Friedman, Allan H. Friedman, Shideng Bao, Qiulian Wu, Qing Shi, James E. Herndon and David A. Reardon. Their work appears in journals such as Neuro-Oncology, Journal of Neuro-Oncology, Journal of Clinical Oncology, Cancer and Archives of Pathology & Laboratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.